Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Feng Huang

Showing results (71-80 of 286) with videos related to

Pageof 29
Sort By:
Plos One|May 5, 2017
Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patientsJee-Fu Huang, Ming-Lun Yeh, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 1, 2017
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experienceMing-Lung Yu, Yao-Li Chen, Chung-Feng Huang, et al.
Alimentary Pharmacology & Therapeutics|December 26, 2025
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral EradicationPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
Medicine|July 12, 2016
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapyChung-Feng Huang, Ming-Lun Yeh, Cing-Yi Huang, et al.
Hepatology International|July 24, 2015
The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter studyChung-Feng Huang, Jee-Fu Huang, Wu-Cheng Chen, et al.
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
The Kaohsiung Journal of Medical Sciences|March 3, 2020
Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodulesZu-Yau Lin, Jing-Houng Wang, Ming-Lun Yeh, et al.
Plos One|January 4, 2013
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirinMing-Lung Yu, Chen-Hua Liu, Chung-Feng Huang, et al.
Diagnostics (Basel, Switzerland)|June 26, 2025
Renal Function in Chronic Hepatitis C Patients in MongoliaGantogtokh Dashjamts, Amin-Erdene Ganzorig, Yumchinsuren Tsedendorj, et al.
Pageof 29

Showing results (71-80 of 286) with videos related to

Sort By:
Pageof 29
Plos One|May 5, 2017
Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patientsJee-Fu Huang, Ming-Lun Yeh, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 1, 2017
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experienceMing-Lung Yu, Yao-Li Chen, Chung-Feng Huang, et al.
Alimentary Pharmacology & Therapeutics|December 26, 2025
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral EradicationPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
Medicine|July 12, 2016
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapyChung-Feng Huang, Ming-Lun Yeh, Cing-Yi Huang, et al.
Hepatology International|July 24, 2015
The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter studyChung-Feng Huang, Jee-Fu Huang, Wu-Cheng Chen, et al.
The Kaohsiung Journal of Medical Sciences|November 5, 2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentTzu-Sheng Cheng, Po-Cheng Liang, Chung-Feng Huang, et al.
The Kaohsiung Journal of Medical Sciences|March 3, 2020
Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodulesZu-Yau Lin, Jing-Houng Wang, Ming-Lun Yeh, et al.
Plos One|January 4, 2013
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirinMing-Lung Yu, Chen-Hua Liu, Chung-Feng Huang, et al.
Diagnostics (Basel, Switzerland)|June 26, 2025
Renal Function in Chronic Hepatitis C Patients in MongoliaGantogtokh Dashjamts, Amin-Erdene Ganzorig, Yumchinsuren Tsedendorj, et al.
Pageof 29